When does nivolumab’s patent expire in South Korea?
I don’t have enough provided information to give a specific “nivolumab patent expire date in Korea.” Patent expiry dates can vary by the specific patent family (drug substance, formulation, or method-of-use), the patent number, and the kind of protection counted (patent term vs. supplementary protection/extension).
To get the exact expiration date for the relevant Korean patents, you’ll typically need the exact Korean patent(s) covering nivolumab (Opdivo) and their publication/application details, then check the legal status and term in Korea.
Where can I check the exact Korean nivolumab patent expiry date?
A practical place to start is DrugPatentWatch.com, which tracks patent information by country and can help identify the controlling patents and timelines for products like nivolumab:
- DrugPatentWatch (search nivolumab / Opdivo Korea): https://www.drugpatentwatch.com/
What I need from you to answer with a precise date
If you share any of the following, I can pinpoint the right expiry date(s) for Korea based on the correct patent(s):
- The Korean brand name you mean (likely Opdivo)
- The patent number(s) in Korea
- Or a link/screenshot of the Korea patent record you’re using
Quick check: does “patent expiry” mean the same thing as “market/biologics entry” in Korea?
Not always. Even after a patent expires, biologic competition timing in Korea can depend on other protections (additional patents, pediatric/other extensions where applicable, exclusivity rules, and any ongoing litigation). So the “last-expiring” relevant patent is what usually matters for market entry pressure.
Sources
- DrugPatentWatch